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Abstract We have previously shown that patients with the
major depressive disorder (MDD) exhibited elevated phos-
phorylation of the lymphocyte glucocorticoid receptor (GR) at
serine 226 (S226). Here, we further analyse potential alter-
ations of GR signalization in lymphocytes of MDD patients,
i.e. the cytoplasmic/nuclear distribution of GR, levels of
FK506-binding protein 5 (FKBP5) and glucocorticoid-
induced leucine zipper (GILZ). The FKBP5 acts as an impor-
tant regulator of GR activation, by decreasing ligand binding
and impeding translocation of the receptor to the nucleus,
while GILZ mediates glucocorticoid anti-inflammatory ef-
fects. Our result showed that the depressed patients had sig-
nificantly higher GR levels in the cytoplasm compared to
controls, which was accompanied by higher FKBP5 levels.
Linear regression model demonstrated significantly higher
correlation between FKBP5 and cytoplasmic GR than the
presence of MDD itself or phosphorylation of nuclear GR at
S226. There were no differences in the levels of GILZ iso-
forms. Therefore, the results suggest that accumulation of
the GR in cytoplasm is related to the elevation of FKBP5,
adding one more step in understanding altered GR signalling
in lymphocytes, and potentially brain tissue, of MDD patients.
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Introduction
Major depressive disorder (MDD) is a complex psychiatric
disorder which pathogenesis involves multiple biological
systems, including disturbed glucocorticoid signalling
(Anacker et al. 2011; Zunszain et al. 2011). The reduced
glucocorticoid receptor (GR) function is believed to underline
alterations in hypothalamic–pituitary–adrenal (HPA) axis ac-
tivity frequently observed in MDD patients, but it is also well
documented in peripheral blood cells (Calfa et al. 2003;
Cattaneo et al. 2013; Menke et al. 2012; Pariante and
Lightman 2008; Pariante and Miller 2001). The periph-
eral tissues, except for being an easy accessible model for
analysing GR signalization in MDD patients, have a potential
to be used as biomarkers for diagnosis and following up the
treatment of depression (Cattaneo et al. 2013; Hepgul et al.
2013; Menke et al. 2012). However, studies of GR function in
leukocytes could also be helpful in understanding crosstalk of
glucocorticoids and immune system, for a long been recog-
nized to be disturbed in depression (Maes 1999; Miller et al.
2009; Zunszain et al. 2011).
The well-known mode of GR action is as follows: in the
absence of glucocorticoids, GR predominantly resides in the
cytoplasm in a multiprotein complex consisting of heat shock
proteins and immunophilins, and upon ligand binding, it
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translocates to the nucleus where it regulates transcription of
numerous genes (Anacker et al. 2011; Heitzer et al. 2007).
One of the important players in regulating this process is
FK506-binding protein 5 (FKBP5), an immunophilin that
when bound to the GR complex lowers the receptor affinity
for its ligand and interfere with its translocation to the nucleus
(Denny et al. 2000; Storer et al. 2011; Wochnik et al. 2005).
Furthermore, FKBP5 expression is induced by glucocorti-
coids, as a part of an intracellular ultra-short negative feedback
loop restraining GR activity (Binder 2009; Vermeer et al.
2003). Increased expression of FKBP5 has already been
linked with susceptibility to depressive and anxiety disorders,
implicating the importance of further exploring the function of
this protein in depression (Binder 2009; Suzuki et al. 2014;
Tatro et al. 2010).
In response to glucocorticoids, GR stimulates a wide vari-
ety of gens, including glucocorticoid-induced leucine zipper
(GILZ), one of the key mediators of glucocorticoid anti-
inflammatory actions (Ayroldi and Riccardi 2009; D’Adamio
et al. 1997). GILZ inhibits the activation of nuclear factor kB
(NF-kB) and activator protein 1 (AP-1), and it may regulate
apoptosis in T lymphocytes (Ayroldi et al. 2001; Ayroldi and
Riccardi 2009). In spite of the mentioned importance of
GILZ’s role in mediating GR anti-inflammatory effects, it
has not been so extensively analysed in depressed patient or
animal models of depression.
We have previously shown altered phosphorylation of nu-
clear GR in lymphocytes of patients with a current depressive
episode (Simic et al. 2013b), and here, we further analyse
potential alterations in GR signalling by assessing GR nuclear/
cytoplasmic distribution and levels of FKBP5 and GILZ, in
lymphocytes of these subjects.
Materials and Methods
Subjects
The subjects were already described in our previous study
(Simic et al. 2013b). Briefly, the study protocol was approved
by the Medical Ethics Committee of Clinical Centre of Serbia.
Thirty patients were selected from the University Clinic for
Psychiatry, Clinical Centre of Serbia, while 35 control sub-
jects were recruited by local advertisements. All subjects gave
their written informed consent prior to entering the study. ICD
X and DSM IV (M.I.N.I.) criteria were used for diagnosing
the current major depressive episode, confirmed by two
trained psychiatrists. All patients had neither a history of
ongoing significant medicine nor neurological conditions,
although a number of subjects had sub-threshold diagnoses
of anxiety disorder. The intensity of depressive symptomatol-
ogy was evaluated by Hamilton Rating Scale for Depression
(HAMD-21), and the recruited patients had moderate to very
severe depression (HAMD>14). All patients were under med-
ical treatment at the time of blood sampling, namely, com-
bined therapy comprising of antidepressants (88.5 % of pa-
tients), benzodiazepines (96.2 % of patients), mood stabilizers
(30.8 % of patients) and antipsychotics (50 % of patients). The
patients were adherent to aforementioned psychiatric drugs for
at least 1 week before the interview. The lifetime exposure to
antidepressants and benzodiazepines varied from several
months to several years.
Blood Sample Collection, Purification of Lymphocytes
and Preparation of the Cell Extracts
Blood sampling, purification of peripheral blood mononuclear
cells (PBMC) and preparation of cellular extract were done as
already described (Simic et al. 2013a, b).
All blood samples for determining cortisol levels and mo-
lecular biology analyses were obtained between 0800 and
0900 h. For obtaining PBMC, blood (10 ml) was drawn in
Na2EDTA BD Vacutainer tubes. PBMC were purified using
lymphocyte separation medium (LSM, MP Biomedicals) ac-
cording to the manufacturer’s protocol. After washing with
cold phosphate-buffered saline (PBS), PBMC pellets were
stored at −80 °C until further preparation.
The cytoplasmic and nuclear extracts from PBMC were
prepared according to mini-extraction protocol with slight
modifications (Sheehan et al. 1998). Briefly, PBMC pellets
were suspended in 500 μl of ice-cold buffer A (10 mM
HEPES pH 7.9) containing 10 mM KCl, 0.1 mM Na2EDTA,
0.1 mMNa2EGTA, 1 mMDTTand protease and phosphatase
inhibitors as defined in our previous papers. The cells were
incubated on ice for 15min, after which 75μl of 10% solution
of Tween 20 was added, the tubes were vortexed vigorously
for 20 s and finally PBMC homogenates were centrifuged at
10,000×g for 7 min at 4 °C. After pouring off the supernatant,
which was used as cytoplasmic extract, nuclear pellets were
suspended in 150 μl of ice-cold buffer C (20 mM HEPES 7.9
pH) containing 400 mM NaCl, 1 mM EDTA, 1 mM EGTA,
1mMDTTand the same protein and phosphatase inhibitors as
in the buffer A. The samples were incubated at 4 °C for 15min
on shaking platform followed by centrifugation at 10,000×g
for 10 min at 4 °C. The obtained supernatants were used as
nuclear extracts (the purity of cellular compartments is pre-
sented in the Supplemental Material). After determining the
protein concentration by BCA Assay kit (SERVA Electropho-
resis), the nuclear extracts were boiled in sample loading
buffer according to Laemmli for 5 min.
Western Blot Analysis
For Western blot analysis, equal amounts of nuclear proteins
(60 μg) were loaded into each well of SDS polyacrylamide gel
(10 or 12 %), separated by electrophoresis and transferred
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onto PVDF membrane (Immobilon-P membrane, Millipore).
After blocking for 1 h in a 5 % non-fat dry milk in PBS,
membranes were incubated with appropriate primary and
secondary antibodies. The following antibodies were used:
GR M-20 (Santa Cruz Biotechnology), FKBP51 H-100
(Santa Cruz Biotechnology) and GILZ D-2 (Santa Cruz Bio-
technology), for detecting the respective proteins. The β-actin
was used as a loading control, detected by specific antibody
(Abcam). The signals were detected using enhanced chemilu-
minescence substrate Pico or Femto (Pierce) and exposing the
membrane to an X-ray film. Densitometry of protein bands on
X-ray film was performed by ImageJ analysis PC software. In
order to compare the protein levels between different blots, an
internal reference sample (IRS) was run on each gel. The
protein levels from all subjects were represented as the per-
centages of respective IRS set as 100 %. All samples were
analysed at least twice. Non-representative signals of the
examined proteins were excluded from further analyses.
Statistical Analyses
Comparisons between patients with MDD and healthy subjects
were performed by t test for continuous variables or by χ2 test
for categorical variables. Logarithmic transformations of vari-
ables with non-parametric distributions were carried out. The
effect of potential covariates was analysed using a general
linear model (GLM). The Pearson’s correlation and linear
regression analyses were used to describe relations between
desired variables. The statistical significance was accepted at
p<0.05. The statistical analyses were performed using SPSS.
Results
Demographic and Clinical Data
The demographic and clinical data of healthy and MDD
subjects are already described in our previous study (Simic
et al. 2013b) but also shown here in Table 1. There was no
statistical difference regarding the gender contributions in
healthy and MDD groups (Table 1). However, the controls
were significantly younger thanMDD patients, and there were
more smokers in MDD than in the healthy group (Table 1).
The concentrations of cortisol were also slightly higher in
depressed patients (Table 1). Indeed, in further analyses, age,
cortisol levels and smoking were considered as covariates.
Increased GR Levels in the Cytoplasm of PBMC of MDD
Patients
Firstly, we compared nuclear and cytoplasmic levels of GR in
the patients and control subjects (Fig. 1a). Therewas a significant
increase of GR in cytoplasm of PBMC of depressed patients
compared to controls (t=−2.51, p=0.015), while there were
no differences in nuclear levels between the groups, as already
reported in our previous paper (Simic et al. 2013b). After
adjustment for age, gender, cortisol and smoking, MDD still
exhibited significant effect on cytoplasmic GR levels
(Table 2), and effects of the covariates were not significant.
Additionally, we analysed if smoking status could contribute
to variances in cytoplasmic/nuclear GR levels in controls and
MDD group separately, but no statistically significant differ-
ences were found. Further, we examined if treatments by
antipsychotics and mood-stabilizers could contribute as well
to variations in GR levels in MDD group (since half the
patients were treated with antipsychotics and about a third
with mood stabilizers). However, patients did not differ in
cytoplasmic/nuclear GR levels depending on weather they
were treated with these medications or not.
Increased FKBP5 in the Cytoplasm of PBMC of MDD
Patients
There was statistically significant increase in FKBP5 in
MDD subjects compared to controls (t=−7.381, p<0.001;
Fig. 1b). Indeed, after adjustment for age, gender, cortisol
and smoking, the effect of the disorder on the levels of
FKBP5 was still significant (Table 2). The effects of any of
the covariates on FKBP5 levels were not significant as
well. As for GR levels, we also examined if differences
between smokers and non-smokers contributed to the var-
iations in FKBP5 levels in control and patient groups
separately but found no statistically significant effects.
Likewise, we analysed if treatments by antipsychotics
and mood stabilizers could affect the variance of FKBP5
levels in MDD group. There was no statistically significant
Table 1 The main sociodemographic and clinical characteristics of the
subjects
Characteristics Healthy
subjects
MDD
patients
Test values
(n=35) (n=30)
Age (years) 39.49±9.64 44.77±7.58 t=−2.423;
p=0.018
Gender (% of women) 54.3 % 56.7 % χ2=0.037;
p=0.847
Cortisol (nmol/l) 348±144 469±157 t=−1.921;
p=0.059
HAMD-17 24.91±7.03
smoking (% of daily
smokers)
31.40 % 70.00 % χ2=9.615;
p=0.002
Data are represented as mean±SD or percentage
MDD major depressive disorder
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difference in FKBP5 levels between patients treated and
non-treated with mood stabilizers. However, patients treat-
ed with antipsychotics did have higher FKBP5 levels than
those not treated with these medications (t=−2.241, p=
0.035), but still, the latter group had higher FKBP5 levels
than controls (t=−4.33, p<0.001).
Secondly, we investigated how the changes in FKBP5
were related to the changes in nuclear GR (published in
our previous study), since FKBP5 is strongly induced
by glucocorticoids. FKBP5 levels positively correlated
with increased levels of GR phosphorylated at S211 and
S226 (FKBP5 and pGR-S211, r=0.324, p=0.012;
FKBP5 and pGR-S226, r=0.555, p<0.001) and nega-
tively with the ratio of pGR-S211/pGR-S226 (r=−0.262,
p=0.044), while there was no correlation with nuclear
GR levels.
No Changes in GILZ Levels in the Cytoplasm of PBMC
of MDD Patients
There were no differences in the levels of GILZ, neither in
isoform of 17 nor 28 kDa between MDD and control subjects
(Fig. 1c). Subsequently, we investigated whether there were
possible associations between GILZ levels and alterations in
nuclear GR, since GILZ expression is known to be stimulated
by glucocorticoids. However, levels of GILZ correlated nei-
ther with nuclear GR levels nor with changes in GR
phosphorylation.
Accumulation of GR in the Cytoplasm Is Primarily Related
to the Elevation of FKBP5
Finally, we analysed whether the accumulation of GR in
cytoplasm, found in MDD patients, was related to increased
cytoplasmic FKBP5 levels. Additionally, we assumed that
elevated phosphorylation of nuclear GR at serine 226, dem-
onstrated in our previous study (Simic et al. 2013b), could also
contribute to the accumulation of GR in the cytoplasm, since it
is known that phosphorylation of this amino acid enhances
GR export from nucleus to cytoplasm (Itoh et al. 2002).
Indeed, the elevation of cytoplasmic GR levels was positively
related to elevation of cytoplasmic FKBP5 levels, on one
hand, and nuclear pGR-S226 levels, on the other hand (cyto-
plasmic GR and FKBP5, r=0.508, p<0.001; cytoplasmic GR
and nuclear pGR-S226, r=0.409, p=0.002; Fig. 2, note that,
on the graphic, the truth levels of analysed proteins are repre-
sented, while in Pearson’s correlations, the transformed values
were used). When patient and control groups were analysed
separately, in both groups, there were also positive correla-
tions between cytoplasmic GR and nuclear pGR-S226 (con-
trols, r=0.267, p=0.17; patients, r=249, p=0.17) and be-
tween cytoplasmic GR and FKBP5, however, only correlation
Fig. 1 Quantified levels and representative Western blots of a cytoplas-
mic and nuclear GR, b FKBB5 and c GILZ in PBMC of healthy and
MDD subjects. The levels of all proteins were adjusted to β-actin, which
served as a loading control, and represented as the percentage of IRS of
each protein. Significant differences were detected applying t test for
MDD versus healthy subjects: *p<0.05; ***p<0.001
Table 2 The effects of MDD on the levels of GR and FKBP5 in
cytoplasm, adjusted for age, gender, cortisol and smoking
Effect of MDD GR FKBP5
Model 1 (no adjustment) F=6.301 F=54.481
p=0.015 p<0.001
Model 2 (adjusted for age) F=5.963 F=55.764
p=0.018 p<0.001
Model 3 (adjusted for gender) F=5.844 F=50.858
p=0.019 p<0.001
Model 4 (adjusted for cortisol) F=5.580 F=54.490
p=0.021 p<0.001
Model 5 (adjusted for smoking) F=4.050 F=42.661
p=0.049 p<0.001
F and p values from GLM univariate analyses are given
MDD major depressive disorder, GR glucocorticoid receptor, FKBP5
FK506-binding protein 5
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of cytoplasmic GR and FKBP5 in patients was significant
(controls, r=0.316, p=0.116; patients, r=0.560; p=0.002).
Then, we run a linear regression model to identify the
relative contributions of the levels of FKBP5 in the cytoplasm,
pGR-S226 in the nucleus and the presence of MDD to predict
GR levels in the cytoplasm (Table 3). It was shown that only
FKBP5 had a significant effect on GR levels in the cytoplasm,
and standardized coefficient was by far higher for FKBP5 than
for other predictors.
Discussion
MDD is known to be characterized by glucocorticoid re-
sistance in both brain and periphery, which in turn could
lead to numerous physiological disturbances, including
hyperactivity of HPA axis and increased inflammation
(Anacker et al. 2011; Zunszain et al. 2011). Among previ-
ous studies analysing GR function in lymphocytes, it was
demonstrated that GR binding was reduced or unchanged
in cytoplasm or whole cell extracts of depressed patients
(Calfa et al. 2003; Pariante and Miller 2001). Herein, we
documented that in lymphocytes of MDD patients, there is
an accumulation of the GR in cytoplasm. Bearing in mind
that GR detection in our samples was achieved by the
Western blot technique, our results cannot be directly com-
pared with results of GR binding studies. Namely, while
Western blot enables us to detect total GR protein levels,
binding assays give information about the ability of the GR
to bind ligand, a feature that could be dependent on other
factors such as its interactions with chaperones. However,
in light of this, our results of elevated cytoplasmic GR
could indicate the reduced capacity of the receptor ligand
binding. Indeed, the elevation of FKBP5 in PBMC cyto-
plasm of MDD patients, which had been shown to reduce
GR affinity for cortisol and its subsequent activation (Da-
vies et al. 2002; Denny et al. 2000; Wochnik et al. 2005),
could support this assumption.
We assumed that this accumulation of GR in the cytoplasm
could be due to decreased import of the receptor to the nucleus
and/or its increased export from the nucleus, although the
changes in nuclear levels of GR were not detected. As it is
already mentioned, elevation of FKBP5 could mediate re-
duced GR import to the nucleus (Davies et al. 2002; Wochnik
et al. 2005), while, on the other hand, elevated GR phosphor-
ylation at S226 could contribute to enhanced nuclear export of
the GR (Itoh et al. 2002). Indeed, it was shown that increased
phosphorylation of GR at S226 contributed to impaired GR
translocation in PBMC of severe asthma patients (Mercado
et al. 2011). Nevertheless, according to our results, it seems
that the accumulation of GR in cytoplasm of lymphocytes
from MDD patients is more likely related to high FKBP5
levels than to the elevation of nuclear pGR-S226. Similarly,
chronic mild stress model of depressive-like behaviour in
laboratory animals revealed accumulation of cytoplasmic
GR in ventral hippocampus and prefrontal cortex which was
related to FKBP5 elevation, rather than increased phosphory-
lation of GR at S246 (rat ortholog of S226) (Guidotti et al.
2013). Therefore, we could suggest that retention of GR in
cytoplasm due to high FKBP5 levels could be one of the
mechanisms contributing glucocorticoid resistance in brain
tissue of depressed patients as well.
Fig. 2 Relations of GR levels in cytoplasm with cytoplasmic FKBP5
levels (a) and nuclear levels of GR phosphorylated at S226 (b) in control
and MDD subjects. The levels of GR and FKBP5 in cytoplasm were
adjusted to β-actin, while the levels of pGR-S226 were adjusted to total
GR levels in the nucleus. The levels of all proteins are represented as
percentages of IRS for respective protein
Table 3 Standardized coefficients and p values of linear regression
model that assessed relative contributions of the levels of FKBP5 in the
cytoplasm, pGR-S226 in the nucleus and presence ofMDD to predict GR
levels in the cytoplasm
Predictors Effect of each predictor on GR levels in cytoplasm
FKBP5 β=0.588, p<0.001
pGR-S226 β=0.089, p=0.420
MDD β=−0.070, p=0.596
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In our previous studies, we showed that increased phos-
phorylation of GR at S226 indicating reduced GR function
was related to increased reports of depression, anxiety and
stress in healthy subjects (Simic et al. 2013a), and further
elevation of pGR-S226 could contribute to further disruption
of GR function in patients with MDD (Simic et al. 2013b).
The present study reveals one more possible mechanism at-
tributing to disturbed GR signalling in MDD patients, that is
the retention of the GR in the cytoplasm related to the in-
creased FKBP5 levels in depressed subjects (correlations of
FKBP5 or cytoplasmic GR and current reports of depression,
anxiety and stress were not significant in healthy subjects; data
not showed). Certainly, it is not surprising that in MDD
patients, there are multiple points at which GR signalling
could be disrupted.
A further possibility that could lead to elevated cytoplasmic
GR levels is reduced degradation of GR in lymphocytes of
MDD patients. However, to our best knowledge, there are no
evidences about the altered degradation of GR related to
MDD. Bering in mind that on one side, agonist binding
markedly reduces GR half-life (Hoeck et al. 1989; Webster
et al. 1997) and, on the other, as already mentioned, the
findings of reduced GR binding in MDD patients (Calfa
et al. 2003; Pariante and Miller 2001), we could hypothesize
that indeed, there might be reduced degradation of GR in
lymphocytes of MDD patients. However, this presumption
should indeed be confirmed by additional experiments.
Our findings of elevated FKBP5 in lymphocytes of MDD
patents are in agreement with previous studies of increased
messenger RNA (mRNA) for FKBP5 in depressed patients
(Cattaneo et al. 2013). Additionally, increased FKBP5 at the
levels of both mRNA and protein was found in the prefrontal
cortex of post-mortem tissue of depressed subjects (Tatro et al.
2009). Concerning the efforts in finding easily accessible
biomarkers that could mirror the changes in brain functioning,
recent data from animal models emphasize the value of
FKBP5, since it was shown that the enhancements of its
expression are comparable between blood and hippocampus
in response to increasing concentrations of corticosterone
(Ewald et al. 2014). It is also well documented that several
gene variants of FKBP5 gene are related to augmented induc-
tion of FKBP5 upon stress exposure (Ising et al. 2008; Luijk
et al. 2010), and the same alleles are associated with increased
susceptibility to depression and anxiety disorders (Binder
et al. 2004; Menke et al. 2013; Minelli et al. 2013; Suzuki
et al. 2014; Szczepankiewicz et al. 2014). Therefore, although
we did not do genotyping in our sample, it is possible that
some of these polymorphisms contributed to higher FKBP5
levels observed in MDD patients in this study as well.
Also, it should be noted that the elevation of FKBP5 in
lymphocytes of MDD patients occurred in spite of increase in
pGR-S226 and decrease in pGR-S211/p-GR-S226 ratio which
suggest reduced GR transcription activity. However, increased
phosphorylation of GR at S211 still might contribute to higher
FKBP5 levels in MDD patients. Additionally, it is probable
that some other mechanisms, beyond the GR phosphorylation,
are responsible for sustaining high FKBP5 levels, such as
epigenetic changes (Klengel et al. 2013; Lee et al. 2010), or
stability of its mRNA molecule (Tatro et al. 2009).
There were no changes in GILZ protein levels between
controls and the patients, either in isoform of 17 or 28 kDa,
and changes in GR phosphorylation did not lead to altered
GILZ levels. No differences in GILZ mRNA levels were
detected in one other previous study, but in the depressed
group of subjects, it was showed that GILZ expression was
negatively related to hippocampal atrophy (Frodl et al.
2012). It is possible that alterations in GILZ levels are
linked to some specific morphological/molecular changes
in MDD patients that we did not examine in this study and,
considering the crosstalk of glucocorticoids and immunity
system, further research of GILZ related to depression we
believe is required.
It could be deemed that a limitation of this study is that all
patients were on medications, at the time of blood sampling.
Our results showed that treatment with antipsychotics could
indeed lead to more elevated FKBP5 levels in MDD patients,
but this treatment did not account for the overall observed
differences between MDD patients and controls. Besides that,
all patients had a significant intensity of depressive symptoms
at the time of their evaluation, implicating limited effects of
the medications. Actually, successful long-term antidepressant
treatments have rather been associated with decreased than to
increased FKBP5 levels (Cattaneo et al. 2013).
In conclusion, our results revealed that accumulation of GR
in the cytoplasm was related to elevation of FKBP5 which
could be one more aspect of disturbed GR signalling in
lymphocytes of MDD patients. Therefore, together with our
previous findings, alterations in GR signalization in PBMC,
and possibly brain tissue of MDD patients, could be related
not only to the altered phosphorylation of GR but also to the
increased FKBP5 contributing the retention of the GR in
cytoplasm.
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